Rare disease biotech Edgewise Therapeutics files for a $100 million IPO

Edgewise Therapeutics, a Phase 1 biotech developing small molecule therapies for rare muscle disorders, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

Edgewise is focused on the discovery, development, and commercialization of innovativeRead More